Sunday, January 18, 2026
Facebook Linkedin Twitter
HomeTagsNEC

NEC

Biotechnology

Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

PR Newswire -
Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a leader in IT, network and...
12Page 2 of 2
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us | Terms & Conditions